| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Simeprevir |
| Brand | Olysio® |
| Indication | In combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients as part of a triple therapy regimen (co-administered with PegInterferon + Ribavirin) to treat hepatitis C virus (HCV) Genotypes 1 and 4 who are treatment naïve or have previously been treated. |
| Assessment Process | |
| Rapid review commissioned | 27/05/2014 |
| Rapid review completed | 11/07/2014 |
| Rapid review outcome | Full pharmacoeconomic assessment not recommended when used in triple therapy with peg-interferon and ribavirin. |
